Capricor Therapeutics (CAPR) Payables (2010 - 2026)

Capricor Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Payables fell 25.23% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 25.23% YoY), while the FY2025 annual figure was $1.7 million, down 49.61% from the prior year.
• Payables for Q1 2026 stood at $3.9 million, up from $1.7 million in the prior quarter.
• The five-year high for Payables was $6.8 million in Q3 2023, with the low at $1.7 million in Q4 2025.
• The 5-year median for Payables is $4.8 million (2022), against an average of $4.7 million.
• The sharpest annual moves came in 2023 and 2025: Payables soared 75.78% in 2023, then tumbled 58.36% in 2025.
• Capricor Therapeutics' Payables stood at $4.8 million in 2022, then climbed by 29.28% to $6.3 million in 2023, then slumped by 47.46% to $3.3 million in 2024, then plunged by 49.61% to $1.7 million in 2025, then soared by 137.37% to $3.9 million in 2026.
• Business Quant data shows CAPR's Payables at $3.9 million in Q1 2026, $1.7 million in Q4 2025, and $2.7 million in Q3 2025.